In a report released today, Marcus Curley from UBS maintained a Buy rating on CSL, with a price target of A$300.00. The company’s shares closed last Friday at $132.43.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curley covers the Healthcare sector, focusing on stocks such as CSL, Resmed, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. According to TipRanks, Curley has an average return of -11.1% and a 43.33% success rate on recommended stocks.
Currently, the analyst consensus on CSL is a Moderate Buy with an average price target of $184.26, a 39.14% upside from current levels. In a report released on September 29, Citi also maintained a Buy rating on the stock with a A$265.00 price target.
The company has a one-year high of $207.00 and a one-year low of $124.73. Currently, CSL has an average volume of 694.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CMXHF in relation to earlier this year.
Read More on CMXHF:
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
